Clinical use of E. coli Nissle 1917 in inflammatory bowel disease - PubMed (original) (raw)
Review
Clinical use of E. coli Nissle 1917 in inflammatory bowel disease
Michael Schultz. Inflamm Bowel Dis. 2008 Jul.
Abstract
The probiotic Escherichia coli strain Nissle 1917 is in addition to some Lactobacilli sp. one of the best-studied probiotic strains. This particular E. coli strain was isolated in 1917 based on its potential to protect from presumably infectious gastroenteritis. Initial therapeutic success was noted in the management of gastrointestinal infectious disorders and infections affecting the urinary tract; the focus shifted later to chronic inflammatory conditions. The unique combination of fitness and survival factors to support intestinal survival, the lack of virulence, and obvious probiotic properties make this microorganism a safe and effective candidate in the treatment of chronic inflammatory bowel diseases. Three large clinical trials have assessed the potential in the maintenance of remission of ulcerative colitis and equivalence to standard 5-ASA medication was documented. This review aims to discuss important mechanisms of E. coli Nissle 1917 and will review the available literature regarding treatment of inflammatory bowel diseases.
Similar articles
- Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
Scaldaferri F, Gerardi V, Mangiola F, Lopetuso LR, Pizzoferrato M, Petito V, Papa A, Stojanovic J, Poscia A, Cammarota G, Gasbarrini A. Scaldaferri F, et al. World J Gastroenterol. 2016 Jun 28;22(24):5505-11. doi: 10.3748/wjg.v22.i24.5505. World J Gastroenterol. 2016. PMID: 27350728 Free PMC article. Review. - Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Petersen AM, et al. J Crohns Colitis. 2014 Nov;8(11):1498-505. doi: 10.1016/j.crohns.2014.06.001. Epub 2014 Jun 25. J Crohns Colitis. 2014. PMID: 24972748 Clinical Trial. - Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Kruis W, et al. Gut. 2004 Nov;53(11):1617-23. doi: 10.1136/gut.2003.037747. Gut. 2004. PMID: 15479682 Free PMC article. Clinical Trial. - Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications.
Zhao Z, Xu S, Zhang W, Wu D, Yang G. Zhao Z, et al. Food Funct. 2022 Jun 6;13(11):5914-5924. doi: 10.1039/d2fo00226d. Food Funct. 2022. PMID: 35583304 Review. - [The role of Escherichia coli strain Nissle 1917 in the gastro-intestinal diseases].
Różańska D, Regulska-Ilow B, Choroszy-Król I, Ilow R. Różańska D, et al. Postepy Hig Med Dosw (Online). 2014 Nov 6;68:1251-6. doi: 10.5604/17322693.1127882. Postepy Hig Med Dosw (Online). 2014. PMID: 25380207 Review. Polish.
Cited by
- Shining a Light on Colibactin Biology.
Dougherty MW, Jobin C. Dougherty MW, et al. Toxins (Basel). 2021 May 12;13(5):346. doi: 10.3390/toxins13050346. Toxins (Basel). 2021. PMID: 34065799 Free PMC article. Review. - Non-pathogenic Trojan horse Nissle1917 triggers mitophagy through PINK1/Parkin pathway to discourage colon cancer.
Wang Y, Liu Y, Su X, Niu L, Li N, Xu C, Sun Z, Guo H, Shen S, Yu M. Wang Y, et al. Mater Today Bio. 2024 Sep 27;29:101273. doi: 10.1016/j.mtbio.2024.101273. eCollection 2024 Dec. Mater Today Bio. 2024. PMID: 39415764 Free PMC article. - Development of Aspirin-Inducible Biosensors in Escherichia coli and SimCells.
Chen JX, Steel H, Wu YH, Wang Y, Xu J, Rampley CPN, Thompson IP, Papachristodoulou A, Huang WE. Chen JX, et al. Appl Environ Microbiol. 2019 Mar 6;85(6):e02959-18. doi: 10.1128/AEM.02959-18. Print 2019 Mar 15. Appl Environ Microbiol. 2019. PMID: 30658983 Free PMC article. - A single-cell nanocoating of probiotics for enhanced amelioration of antibiotic-associated diarrhea.
Pan J, Gong G, Wang Q, Shang J, He Y, Catania C, Birnbaum D, Li Y, Jia Z, Zhang Y, Joshi NS, Guo J. Pan J, et al. Nat Commun. 2022 Apr 19;13(1):2117. doi: 10.1038/s41467-022-29672-z. Nat Commun. 2022. PMID: 35440537 Free PMC article. - An Intestinal Th17 Subset is Associated with Inflammation in Crohn's Disease and Activated by Adherent-invasive Escherichia coli.
Paroni M, Leccese G, Ranzani V, Moschetti G, Chiara M, Perillo F, Ferri S, Clemente F, Noviello D, Conforti FS, Ferrero S, Karnani B, Bosotti R, Vasco C, Curti S, Crosti MC, Gruarin P, Rossetti G, Conte MP, Vecchi M, Pagani M, Landini P, Facciotti F, Abrignani S, Caprioli F, Geginat J. Paroni M, et al. J Crohns Colitis. 2023 Dec 30;17(12):1988-2001. doi: 10.1093/ecco-jcc/jjad119. J Crohns Colitis. 2023. PMID: 37462681 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources